With the support of Pfizer, the University Hospital of Ghent will give their rheumatic patients a Striiv wearable to measure pain, fatigue, sleep and general rheumatic level on a daily basis.
How do they measure pain, fatigue…?
Rheumatoid arthritis is a chronic inflammatory disorder which affects the small joints in person’s hands and feet. It is an autoimmune disease, where an individual’s immune system attacks joint tissues and potentially other body parts which is caused by unknown reasons. Rheumatoid Arthritis affects around 17.6 million people worldwide, with more than 1.6 million people in the United States and 6.2 million people in Europe. The disorder can occur at any age but it usually occurs after age 40, and it affects more frequently women rather than men. Typical symptoms cause people to feel sick, tired as well as feverish and it affects joints symmetrically.
Striiv is a San-Francisco based company now on its ninth generation of wearables. The company first started with physical wearables in the welness sector but quickly switched its focus to the healthcare sector, more precisely data valorization. Their wearables are designed to be easy to use with a quick ability to plug and play. Their partnership with Pfizer includes developing digital therapies and medication in order to achieve best outcomes.
LynxCare will use it’s AI engine & calculation module to generate real time insights on an individual level, hospital level and inter hospital aggregation. This way the treating physician can use these insights to alter the medication protocol based on real world data that the patient “feeds” to its caregivers.
What outcome points?
The goal of this initial pilot is to evaluate the feasibility and use of these extra data insights to optimize treatment protocols. In a next phase the wearable data will be aggregated with clinical outcome data extracted from the EMR to support physicians in their daily decision making.